Significance of Rosiglitazone Inhibiting TLR4 Expression in Partial Hepatic Ischemia/Reperfusion of Mice

The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor γ (PPARγ) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BABL/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. The model of the mouse partial hepatic ische- mia/reperfusion injury was established. All the animals were randomly divided into 3 groups: rosiglitazone group, vehicle (dimethylsulphoxide, DMSO) group and sham operation group. The hepatic samples were collected when mice were sacrificed 0, 2, 4 and 6 h after reperfusion following 1 h ischemia to analyze the acute phase of hepatic IRI. The dynamic expression of TlR4 mRNA was de- tected quantitatively by real-time-PCR, and the levels of TNF-α, IL-10 and ALT in portal vein were determined in all groups. After restoration of blood supply, the expression of TLR4 mRNA in ischemic lobes was detected in 0, 2, 4 and 6 h after reperfusion following 1 h ischemia in rosiglitazone group and vehicle group. The most intensive expression of TLR4 mRNA was present at 4 h after reperfusion in ischemic lobes in vehicle group. As compared with vehicle group, the expression of TLR4 mRNA in ischemic lobes in rosiglitazone group was significantly decreased at 4 h after reper- fusion. The level of IL-10 in portal vein was markedly up-regulated in rosiglitazone group as compared with vehicle group. Contrarily, the levels of TNF-α and ALT in portal vein were markedly down-regulated in rosiglitazone group as compared with vehicle group at every time point in mouse partial hepatic IRI model. Rosiglitazone could alleviate the hepatic IRI by inhibiting TLR4 receptor-mediated inherent immune response.     

淋巴细胞CD4+与CD8+比值、N末端脑钠肽前体及白细胞介素6对感染性休克病人预后评估的价值

目的：探讨淋巴细胞CD4⁺与CD8⁺比值(CD4⁺/CD8⁺)、N末端脑钠肽前体(NT-proBNP)及白细胞介素6(IL-6)对感染性休克病人预后评估的价值。方法：选取收治的感染性休克病人77例进行前瞻性研究,检测病人诊断感染性休克第一个24 h内的CD4⁺/CD8⁺、NT-proBNP及IL-6、最高乳酸(Lac)水平,并记录病人性别、年龄、急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分、是否合并基础病等资料。采用logistic回归分析感染性休克病人发生死亡的相关独立危险因素,将CD4⁺/CD8⁺、NT-proBNP及IL-6分别与APACHEⅡ评分进行直线相关回归分析;绘制受试者工作特(ROC)曲线分析CD4⁺/CD8⁺、NT-proBNP及IL-6对感染性休克病人预后评估的价值。结果：感染性休克死亡组NT-proBNP及IL-6水平明显高于存活组(P...     

肺癌A549放射抗拒细胞亚系的建立及抗拒机制的研究

目的 建立肺癌细胞系A549的放射抗拒模型并探讨放射抗拒的机制。方法 应用两种方案对非小细胞肺癌A549细胞系进行X射线照射:一组照射5次,每次剂量600 cGy;另一组照射15次,每次剂量200 cGy。照射完成后对存活细胞单克隆化分别命名为A549-S1和A549-S2,采用克隆形成实验测定两种细胞亚系及亲本A549细胞的放射敏感性,流式细胞术检测细胞周期特征,RT-PCR和Western blot分别测定3种细胞Notch1的表达。结果 与亲本A549细胞相比,A549-S1细胞显示出明显放射抗性,D₀、D_q及N值增大,细胞存活曲线肩区增宽,在SF₂水平上,放射抗性是A549的1.38倍,细胞的S期比例较A549细胞明显增高, G₀/G₁期比例下降(P<0.05),Notch1的表达较A549细胞明显增强。而A549-S2的放射敏感性与亲本细胞相比稍增强,D₀、D_q及N值均减小,细胞存活曲线肩区变窄,在SF₂水平上,放射抗性是A549细胞的0.84倍,细胞S期、G₀/G₁期比例较A549细胞减少,而G₂/M期比例明显增加(P<0.05),Notch1表达与亲本A549细胞相比无明显变化。结论 A549细胞亚系放射抗拒的形成与不同照射方案有一定关系,得出的放射抗拒细胞亚系显示出与亲本不同的细胞周期特征,而细胞特征的变化可能与Notch1的表达增强有关。     

Expert consensus on emergency procedures for portal hypertension bleeding (2022)

Expert consensus proposes an emergency treatment protocol for portal hypertension bleeding. Herein, the emergency treatment procedures, which include first aid, medical, interventional, and surgical treatments, are described. In addition, the indications, contraindications, operating norms, precautions, and prevention of complications of portal hypertension are described to optimize the first aid process.     

辛伐他汀对脂多糖诱导人THP-1单核细胞MCP-1表达的影响

【目的】研究辛伐他汀对脂多糖(LPS)诱导人THP-1单核细胞表达单核细胞趋化蛋白-1(MCP-1)的影响,探讨辛伐他汀的抗炎作用。【方法】体外培养人THP-1单核细胞,分为对照组、LPS组、辛伐他汀低、中、高浓度组,辛伐他汀三组加入不同浓度辛伐他汀预孵2h与LPS组均加入LPS刺激24h,应用Westernblot与ELISA法分别检测各组细胞蛋白与培养基上清中MCP-1水平。【结果】LPS诱导人THP-1单核细胞MCP-1表达显著增加,辛伐他汀呈浓度依赖性显著抑制LPS诱导人THP-1单核细胞MCP-1表达。【结论】辛伐他汀能够抑制LPS诱导人THP-1单核细胞MCP-1表达,提示其具有抗炎作用。     

How to choose clipping versus coiling in treating intracranial aneurysms

BackgroundAfter the decision is made to treat an intracranial aneurysm, clinicians must choose between two competing treatment options; open surgery or endovascular therapy. The rationale underlying the choice of treatment modality is usually unclear, as there is little good quality evidence available.MethodsWe discuss the patient and aneurysm-related factors cited in the neurovascular literature that are considered to influence aneurysm treatment choices.ResultsThe relevance and direction of influence of rupture status, age, type of presentation, and general medical condition, as well as aneurysm size, location, morphology, and multiplicity are discussed. The validity of these factors in influencing treatment decisions remains unclear, with frequently opposing views on the same factor by clinicians practicing opposing techniques. Perceived differences in efficacy and safety of the two different treatment approaches are commonly used in an attempt to justify treatment choices. Difficulties with treatment selection and case-by-case reasoning are reviewed.ConclusionProperly designed and conducted randomized trials are necessary in order to settle the controversy and to determine the optimal treatment modality for intracranial aneurysms. In the absence of reliable knowledge on which to base treatment decisions, the ethically appropriate choice for any clinician, from surgical or endovascular backgrounds, is to participate in randomized trials.